<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Noncirrhotic portal hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Noncirrhotic portal hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Noncirrhotic portal hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Garcia-Pagán, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason Chang Pik Eu, MBBS, MRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Portal hypertension is defined by a pathologic increase in the pressure of the portal venous system. Cirrhosis is the most common cause of portal hypertension, but it can also be present in the absence of cirrhosis, a condition referred to as "noncirrhotic portal hypertension."</p><p>This topic will discuss the etiology of noncirrhotic portal hypertension and two disorders associated with noncirrhotic portal hypertension: schistosomiasis and idiopathic noncirrhotic portal hypertension (INCPH). Other causes of noncirrhotic portal hypertension are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3562.html" rel="external">"Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1679.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Extrarenal manifestations", section on 'Hepatic cysts'</a> and  <a class="medical medical_review" href="/d/html/3588.html" rel="external">"Diagnosis and management of cystic lesions of the liver", section on 'Polycystic liver disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3619.html" rel="external">"Acute fatty liver of pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse hepatic effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3582.html" rel="external">"Evaluation of the adult patient with hepatic granuloma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Restrictive cardiomyopathy'</a>.)</p><p></p><p class="headingAnchor" id="H64319454"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Disorders associated with noncirrhotic portal hypertension can be categorized based on their site of involvement into prehepatic, intrahepatic or posthepatic causes. Intrahepatic causes can be further subcategorized as presinusoidal, sinusoidal, and postsinusoidal  (<a class="graphic graphic_table graphicRef76516" href="/d/graphic/76516.html" rel="external">table 1</a>). In some cases, a given disorder may affect multiple sites (eg, vinyl chloride toxicity, Gaucher disease).</p><p class="headingAnchor" id="H64319853"><span class="h2">Prehepatic and posthepatic causes</span><span class="headingEndMark"> — </span>Prehepatic causes include disruption of the vascular system proximal to the liver, such as portal or splenic vein thrombosis and splanchnic arteriovenous fistulas. </p><p>Posthepatic causes include disruption of the vascular system distal to the liver, such as obstruction of the hepatic veins or the inferior vena cava (eg, Budd-Chiari syndrome) and cardiac diseases (eg, constrictive pericarditis and restrictive cardiomyopathy).</p><p class="headingAnchor" id="H64319860"><span class="h2">Intrahepatic causes</span><span class="headingEndMark"> — </span>The intrahepatic causes of noncirrhotic portal hypertension may be presinusoidal, sinusoidal, or postsinusoidal.</p><p class="headingAnchor" id="H64319867"><span class="h3">Presinusoidal causes</span><span class="headingEndMark"> — </span>Presinusoidal causes of noncirrhotic portal hypertension include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Developmental abnormalities (eg, adult polycystic liver disease, congenital hepatic fibrosis, arteriovenous fistulas).</p><p class="bulletIndent1"><span class="glyph">●</span>Biliary diseases (eg, biliary cholangitis, autoimmune cholangiopathy, primary sclerosing cholangitis, toxic biliary injury from vinyl chloride).</p><p class="bulletIndent1"><span class="glyph">●</span>Neoplastic occlusion of the intrahepatic portal vein (eg, due to lymphoma, epithelioid hemangioendothelioma, epithelial malignancies, chronic lymphocytic leukemia).</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous liver lesions (eg, schistosomiasis, <a class="drug drug_general" data-topicid="10213" href="/d/drug information/10213.html" rel="external">mineral oil</a> granuloma, sarcoidosis).</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic noncirrhotic portal hypertension (INCPH). The term porto-sinusoidal vascular disease (PSVD) has been proposed to encompass a broader group of vascular liver diseases [<a href="#rid2">2</a>]. (See <a class="local">'Porto-sinusoidal vascular disease'</a> below.) </p><p></p><p class="headingAnchor" id="H64319886"><span class="h3">Sinusoidal causes</span><span class="headingEndMark"> — </span>Sinusoidal causes of noncirrhotic portal hypertension include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrosis of the space of Disse, which may be metabolic (eg, nonalcohol-associated fatty liver disease, Zellweger syndrome), inflammatory (viral hepatitis, chronic Q fever, prior cytomegalovirus, schistosomiasis), or induced by drugs or toxins (eg, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, alcohol, vinyl chloride, copper) [<a href="#rid3">3-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amyloid or light-chain deposition in the space of Disse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defenestration of the sinusoidal lining in early alcohol-associated liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinusoidal destruction or collapse in the setting of acute hepatic injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infiltrative diseases such as mastocytosis, Gaucher disease, and idiopathic myeloid metaplasia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compression of sinusoids by markedly hypertrophied hepatocytes, which may be seen with microvesicular steatosis.</p><p></p><p class="headingAnchor" id="H64319893"><span class="h3">Postsinusoidal causes</span><span class="headingEndMark"> — </span>Postsinusoidal causes of noncirrhotic portal hypertension include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sinusoidal obstruction syndrome (previously called veno-occlusive disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Budd-Chiari syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Phlebosclerosis of hepatic veins (eg, due to alcohol-associated liver disease, chronic radiation injury, hypervitaminosis A)</p><p class="bulletIndent1"><span class="glyph">●</span>Primary vascular malignancies (eg, epithelioid hemangioendothelioma, angiosarcoma)</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous phlebitis (eg, from sarcoidosis, <em>Mycobacterium avium</em> or <em>M. intracellulare</em> infection)</p><p class="bulletIndent1"><span class="glyph">●</span>Lipogranulomas (eg, <a class="drug drug_general" data-topicid="10213" href="/d/drug information/10213.html" rel="external">mineral oil</a> granuloma)</p><p></p><p class="headingAnchor" id="H64323358"><span class="h1">SCHISTOSOMIASIS</span><span class="headingEndMark"> — </span>Schistosomiasis is one of the most common causes of noncirrhotic portal hypertension worldwide [<a href="#rid7">7</a>]. Of the three main Schistosoma species, <em>S. japonicum</em> and <em>S. mansoni</em> are known to cause liver disease. <em>S. hematobium</em> affects mainly the urinary tract, although at advanced stages the liver can develop portal fibrosis. The acute stage of schistosomiasis mimics acute bacterial infection and is accompanied by marked eosinophilia. Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly, and splenomegaly with hypersplenism. The diagnosis of schistosomiasis can be made by the detection of schistosomal ova in the stool. Management includes treating underlying parasitic infection and preventing or treating the consequences of portal hypertension. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/5682.html" rel="external">"Schistosomiasis: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention"</a>.)</p><p><em>S. japonicum</em> is distributed widely throughout the world, predominantly in Asia. <em>S. mansoni</em> is endemic in Egypt, Africa, the Middle East, and South America. Two other species (<em>S. mekongi</em> and <em>S. intercalatum</em>) also cause hepatic infections in endemic areas in Southeast Asia and Western Africa, respectively.</p><p class="headingAnchor" id="H64323364"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The infection occurs when the schistosomal cercariae enter the body through the skin. Adult worms eventually find their way to inhabit tributaries of the inferior (<em>S. mansoni</em>) or superior (<em>S. japonicum</em>) mesenteric veins, where they produce hundreds to thousands eggs per day for several years before the end of their lifespan  (<a class="graphic graphic_figure graphicRef90007" href="/d/graphic/90007.html" rel="external">figure 1</a>). Some of these eggs pass through the intestinal mucosa and are excreted in the urine or feces to continue their life cycle. Others flow into the portal vein tributaries and become trapped in the terminal portal venules, where they induce chronic inflammation that is subsequently followed by marked fibrosis. <em>S. japonicum</em> is capable of producing far more eggs than <em>S. mansoni</em> and thus causes more severe liver disease [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a>.)</p><p>In the early stages of infection, the portal resistance is mainly presinusoidal. However, as the fibrotic changes in the portal tracts progress, lobular distortion at the sinusoidal level occurs. This results in an increase in resistance to portal venous flow, as evidenced by an increased wedged hepatic venous pressure (WHVP) in advanced cases [<a href="#rid10">10</a>]. Hemodynamic studies in patients with hepatic schistosomiasis have demonstrated a hyperdynamic systemic and splanchnic circulation with normal hepatic venous pressure gradient (HVPG) and total hepatic blood flow [<a href="#rid8">8,11,12</a>]. (See  <a class="medical medical_review" href="/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Hepatic venous pressure gradient'</a>.)</p><p class="headingAnchor" id="H64323370"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly, and splenomegaly with hypersplenism. In children, chronic infection is associated with growth delay. Many patients with mild fibrosis are asymptomatic during the earlier phases of their disease. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations", section on 'Hepatosplenic schistosomiasis'</a>.)</p><p>Underlying hepatic function remains preserved in hepatic schistosomiasis, and hepatic encephalopathy, ascites, and liver failure are uncommon. Patients with hepatic schistosomiasis usually tolerate episodes of acute variceal bleeding better than patients with cirrhosis because of their preserved liver function. In advanced cases, hepatic decompensation may develop, with hypoalbuminemia and chronic ascites. However, this tends to occur in patients with coexisting liver disease such as chronic viral hepatitis B or C virus infection. These coexisting liver diseases have been found to aggravate the course of hepatic schistosomiasis, changing its natural history [<a href="#rid13">13-15</a>]. Extrahepatic manifestations, such as pneumonia and pulmonary hypertension, have been described in <em>S. mansoni</em> infection [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations", section on 'Hepatosplenic schistosomiasis'</a>.)</p><p class="headingAnchor" id="H64323394"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of schistosomiasis can be made by the detection of schistosomal eggs in the stool  (<a class="graphic graphic_picture graphicRef58729" href="/d/graphic/58729.html" rel="external">picture 1</a>). As an alternative, it can be demonstrated in biopsies of the rectal mucosa  (<a class="graphic graphic_picture graphicRef88449" href="/d/graphic/88449.html" rel="external">picture 2</a>) or the liver. Because the worms concentrate more densely in the distal colon, the rectal mucosa has a heavy load of schistosomal eggs. The diagnosis can also be made using various immunologic assays [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/5682.html" rel="external">"Schistosomiasis: Diagnosis"</a>.)</p><p>The diagnosis of esophageal and/or gastric varices in schistosomiasis is established with endoscopy. However, access to endoscopy can be challenging in the areas of the world where schistosomiasis is endemic. Several studies have examined the role of non-invasive tests for the diagnosis of portal hypertensive complications of schistosomiasis [<a href="#rid18">18</a>]. Most studies focus on the role of ultrasound and hematologic parameters. Sonographic features such as portal vein diameter, spleen size, and periportal fibrosis were predictive of large varices and variceal bleeding [<a href="#rid19">19</a>]. A sonographic score assessing the degree of echogenic periportal thickening and portal vein dilation was shown to correlate with the presence and grade of varices and risk of variceal bleeding [<a href="#rid20">20</a>]. The platelet count/spleen diameter ratio demonstrated high sensitivity (85 to 100 percent) and specificity (83 to 92 percent) for predicting esophageal varices in patients with schistosomiasis [<a href="#rid21">21,22</a>]. </p><p class="headingAnchor" id="H64323400"><span class="h2">Management</span><span class="headingEndMark"> — </span>Antihelminthic treatment (eg, <a class="drug drug_general" data-topicid="9805" href="/d/drug information/9805.html" rel="external">praziquantel</a>, oxamniquine) is active against all forms of human schistosomiasis and is effective for eradicating the worms in the acute stage of the disease. Cure rates vary from 60 to 90 percent for <em>S. mansoni</em> and 60 to 80 percent for <em>S. japonicum</em> [<a href="#rid23">23,24</a>]. Even if treatment does not eradicate all the worms, it will result in a sharp reduction in egg laying. In patients with chronic schistosomiasis, the worms no longer lay eggs and the patient may not require any specific antihelminthic treatment. (See  <a class="medical medical_review" href="/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention", section on 'Treatment'</a>.)</p><p>In addition to treating the underlying parasitic infection, management should be aimed at preventing or treating the consequences of portal hypertension (predominantly variceal bleeding). Only a few studies have described treatment options in these patients. As a result, patients are typically managed similarly to patients with varices in the setting of cirrhosis [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Complications of portal hypertension'</a>.)</p><p>Treatment for acute variceal bleeding includes early pharmacologic treatment with vasoactive drugs, early endoscopic control of bleeding, careful blood product replacement, and prophylactic antibiotics. (See  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a>.)</p><p>Primary and secondary prevention of variceal bleeding includes the use of nonselective beta blockers and endoscopic variceal ligation. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a> and  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p>Data on treatment for hepatic schistosomiasis complicated by portal hypertension and variceal bleeding are limited, and the optimal approach is uncertain [<a href="#rid18">18,26,27</a>]. In a study including 82 patients with schistosomiasis and portal hypertension-related bleeding, beta blocker therapy was associated a longer median time to rebleeding compared with placebo (589 versus 252 days) [<a href="#rid18">18,26</a>]. In a review of 16 studies involving endoscopic therapy for variceal bleeding related to schistosomiasis, sclerotherapy was used in most studies, while some studies evaluated band ligation [<a href="#rid18">18</a>]. Overall, endoscopic therapy was associated with lower mortality rates. However, sclerotherapy was associated with recurrent bleeding rates of approximately 30 percent, which was partially attributed to limited adherence to follow up endoscopy sessions.</p><p>Surgery has been used for patients with noncirrhotic portal hypertension from schistosomiasis who have recurrent variceal bleeding despite medical and endoscopic treatment [<a href="#rid28">28</a>]. Surgical options included splenectomy with esophagogastric devascularization or selective shunts (eg, distal splenorenal shunts) [<a href="#rid29">29,30</a>]. In a trial of 47 patients with schistosomiasis and a history of variceal bleeding, patients treated with splenectomy and esophageal devascularization had a lower rate of recurrent bleeding compared with patients treated with endoscopic sclerotherapy (9 versus 36 percent) [<a href="#rid30">30</a>]. Nonselective shunts (eg, proximal splenorenal shunts) are not recommended because they are associated with high rates of hepatic encephalopathy, hemolysis, and death [<a href="#rid31">31</a>].</p><p>Transjugular intrahepatic portosystemic shunt (TIPS) placement may be an alternative to surgery, but data are limited [<a href="#rid18">18,29,32</a>]. (See  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.) </p><p>Studies have suggested that TIPS was associated with reduced variceal size and lower risk of recurrent bleeding but may be complicated by hepatic encephalopathy. In a cohort of 20 patients with schistosomiasis who had TIPS placement, hepatic encephalopathy was reported in 25 percent of patients, variceal rebleeding in 15 percent of patients, and mortality in 15 percent of patients [<a href="#rid32">32</a>]. Additional studies are required to establish the role of TIPS for patients with noncirrhotic portal hypertension due to schistosomiasis. </p><p class="headingAnchor" id="H2788764828"><span class="h1">IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION/PORTO-SINUSOIDAL VASCULAR DISEASE</span></p><p class="headingAnchor" id="H220711350"><span class="h2">Terminology and diagnostic criteria</span></p><p class="headingAnchor" id="H3924812827"><span class="h3">Idiopathic noncirrhotic portal hypertension</span><span class="headingEndMark"> — </span>Idiopathic noncirrhotic portal hypertension (INCPH) is characterized by the presence of portal hypertension in the absence of cirrhosis on liver histology, the exclusion of obstruction of the extrahepatic portal vein or hepatic venous outflow tract and exclusion of conditions that may cause cirrhosis or noncirrhotic portal hypertension (e.g. congenital hepatic fibrosis, sarcoidosis, schistosomiasis) [<a href="#rid1">1</a>]. </p><p>The diagnosis of INCPH requires that the following criteria are met [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical signs of portal hypertension (at least one of the following) must be present:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Splenomegaly/hypersplenism in conjunction with another sign of portal hypertension.</p><p class="bulletIndent2"><span class="glyph">•</span>Esophageal and/or gastric varices.</p><p class="bulletIndent2"><span class="glyph">•</span>Ascites (nonmalignant).</p><p class="bulletIndent2"><span class="glyph">•</span>Portovenous collaterals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of cirrhosis on liver biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of chronic liver disease that may cause either cirrhosis or noncirrhotic portal hypertension:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic hepatitis B or C virus infection (see  <a class="medical medical_review" href="/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Diagnostic techniques'</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Nonalcohol-associated steatohepatitis (see  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'Diagnosis'</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol-associated steatohepatitis (see  <a class="medical medical_review" href="/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis", section on 'Diagnosis'</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune hepatitis (see  <a class="medical medical_review" href="/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis"</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary hemochromatosis (see  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Diagnosis'</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Wilson disease (see  <a class="medical medical_review" href="/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Diagnostic evaluation'</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Primary biliary cholangitis (see  <a class="medical medical_review" href="/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis", section on 'Diagnosis'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of other conditions that may cause noncirrhotic portal hypertension (eg, congenital liver fibrosis, sarcoidosis (see  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>), schistosomiasis (see <a class="local">'Schistosomiasis'</a> above), myeloproliferative disease, hepatic arterioportal shunts). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging showing patent portal and hepatic veins.</p><p></p><p class="headingAnchor" id="H1335115604"><span class="h3">Porto-sinusoidal vascular disease</span><span class="headingEndMark"> — </span>To recognize that histologic findings of INCPH are not unique to patients with portal hypertension, the clinical entity of porto-sinusoidal vascular disease (PSVD) was described to include the following groups [<a href="#rid2">2,33-35</a>] (see <a class="local">'Terminology and diagnostic criteria'</a> above and <a class="local">'Liver pathology'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with histologic features of INCPH on liver biopsy (eg, obliterative venopathy, nodular regenerative hyperplasia, incomplete septal cirrhosis) but without clinical manifestations of portal hypertension (eg, esophageal or gastric varices).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with histologic features of INCPH on liver biopsy who also have coexisting liver disease (eg, alcohol-related, metabolic syndrome, viral hepatitis) or extrahepatic portal vein thrombosis.</p><p></p><p>The liver biopsy specimen must be adequate (ie, greater than 8 to 10 portal tracts) to assess for these histologic features. </p><p>PSVD without portal hypertension is frequently seen in the setting of autoimmune, hematologic, thrombotic, or drug-induced diseases [<a href="#rid2">2</a>]. </p><p>In addition to histologic features, the diagnosis of INCPH relies on excluding coexisting liver disease and demonstrating patent hepatic vessels on imaging. However, several limitations to the definition of INCPH have been recognized (see <a class="local">'Idiopathic noncirrhotic portal hypertension'</a> above). INCPH cannot be diagnosed if portal vein thrombosis is present on imaging. However, it has been recognized that the portal vein thrombosis is a frequent complication of INCPH during its course. Secondly, these criteria require the exclusion of other causes of liver disease (eg, alcohol, viral hepatitis). However, it has been recognized that other conditions may coexist in patients with INCPH but are clearly not responsible for portal hypertension. Thirdly, the criteria require clinical signs of portal hypertension. However, early stages of the disease have been recognized in which histologic features (eg, obliterative venopathy, nodular regenerative hyperplasia, incomplete septal cirrhosis) are found on liver biopsy in the absence of clinical signs of portal hypertension. These limitations for diagnosing INCPH led a group of experts in vascular liver disease (The Vascular Liver Disease Interest Group [VALDIG]) to propose the term porto-sinusoidal vascular disease (PSVD) to describe a broader spectrum of disease and include these groups of patients [<a href="#rid2">2,35</a>]. </p><p class="headingAnchor" id="H3"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>The incidence of INCPH (or PSVD with portal hypertension) varies worldwide. Older studies suggested that it accounts for approximately 23 percent of cases of portal hypertension in India In other countries (eg, Japan, Netherlands), it was thought to account for 14 to 27 percent of cases of noncirrhotic portal hypertension [<a href="#rid36">36-38</a>]. However, over time, fewer cases have been reported, suggesting that the incidence may be much lower [<a href="#rid1">1,39</a>].</p><p>In Eastern countries, the disease is often encountered in patients who are socioeconomically disadvantaged [<a href="#rid40">40</a>]. Slight differences in the sex and age distribution have been reported from different countries [<a href="#rid41">41,42</a>]. The reason for this is not clear, but differences in socioeconomic status, living conditions, pathogen exposure, average life span, and ethnicity may play a role. In Japan, the incidence of INCPH has declined over time, possibly because of improvements in hygiene and living standards [<a href="#rid42">42</a>]. The incidence of PSVD without PH is uncertain.</p><p class="headingAnchor" id="H4"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The etiology of INCPH (PSVD with portal hypertension) is unknown. However, several pathophysiologic mechanisms are believed to be involved, including chronic or recurrent infections, exposures to drugs or toxins, immunologic disorders, genetic disorders, and hypercoagulability. A large number of disorders, medications, and toxins have been associated with INCPH  (<a class="graphic graphic_table graphicRef50663" href="/d/graphic/50663.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic or recurrent infections – Repeated episodes of umbilical sepsis, bacterial infections, and diarrhea in early childhood (all relatively common in socioeconomically disadvantaged populations) are believed to lead to portal pyemia and pylephlebitis, which may subsequently cause vascular endothelial injury, microthrombosis, sclerosis, and obstruction of small- and medium-sized portal vein radicals. This may subsequently lead to the development of INCPH in early adulthood [<a href="#rid43">43</a>]. Supporting this hypothesis, animal studies involving repeated injections of <em>Escherichia coli</em> into the portal system of rabbits resulted in the development of noncirrhotic portal fibrosis [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs and toxins – Drugs and toxins may induce fibrosis in the space of Disse, leading to INCPH [<a href="#rid1">1</a>]. Drugs associated with INCPH include <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and several cytotoxic drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human immunodeficiency virus (HIV) infection – There have been reports of patients with HIV infection who develop variceal bleeding due to underlying noncirrhotic portal hypertension [<a href="#rid45">45-50</a>]. The pathogenesis is thought to be related to the effect of highly active antiretroviral treatment (particularly long-term exposure to <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a>) on the microvasculature of the liver or the direct effect of the HIV itself [<a href="#rid47">47,51</a>]. The discontinuation of didanosine has been reported in some studies to reduce the progression of INCPH [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altered immune response – Several alterations in the immunologic response have been described in patients with INCPH [<a href="#rid54">54,55</a>]. In addition, different autoimmune diseases are frequently associated with INCPH  (<a class="graphic graphic_table graphicRef50663" href="/d/graphic/50663.html" rel="external">table 2</a>) [<a href="#rid56">56-58</a>]. Anti-DNA antibodies are demonstrable in more than 65 percent of Japanese women with INCPH [<a href="#rid56">56</a>]. Studies have also reported the presence of INCPH and portal systemic collaterals in some patients with severe primary antibody deficiencies [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic predisposition – Few studies have shown potential genetic mechanisms involved in the development of INCPH. In a study of eight patients with early onset noncirrhotic portal hypertension, a shared mutation in DGUOK, a deoxyguanosine kinase required for mitochondrial DNA replication, was identified [<a href="#rid60">60</a>]. Familial aggregation of INCPH and a high frequency of HLA-DR3 have been observed, suggesting a potential genetic pathogenesis [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercoagulability – Some studies have suggested an association of INCPH with a hypercoagulable state. A study of INCPH in 28 Western patients found evidence of various prothrombotic disorders in 50 percent of patients [<a href="#rid62">62</a>]. Over the course of follow-up, 13 patients developed portal vein thrombosis within a median of 7.6 years (range 1 to 21 years). The authors advocated anticoagulant therapy in patients with INCPH found to have a prothrombotic disorder. Similarly, a report from Turkey described extrahepatic portal vein thrombosis in 7 of 34 (20 percent) patients with INCPH over a five-year follow-up period [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous – Preliminary observations have described a role for endothelin-1, nitric oxide, and connective tissue growth factor in development of INCPH [<a href="#rid64">64-68</a>].</p><p></p><p>These risk factors have been also found in patients with PSVD without portal hypertension. </p><p>It has been proposed that a central event in the development of INCPH/PSVD is a portal venopathy caused by thrombosis or obliteration due to hypercoagulability, endothelial injury, or autoimmune injury (from immune complex deposition, autoantibodies, or activated T cells) [<a href="#rid36">36,69-73</a>].</p><p>A vascular cause of INCPH is supported by experimental studies in animals and histologic findings in humans. Blockage of the portal veins decreases blood flow to the liver, resulting in ischemia of the supplied hepatic parenchyma [<a href="#rid74">74</a>]. Ischemia leads to atrophy of the more vulnerable regions of the liver around the central vein and compensatory hypertrophy of the less vulnerable periportal areas [<a href="#rid75">75</a>]. Studies of human livers from patients with acute or chronic portal vein thrombosis have demonstrated apoptosis, atrophy, and the development of nodules [<a href="#rid74">74</a>]. In some cases, the primary insult to the liver was arterial rather than venous. The resulting periportal inflammation eventually leads to portal venopathy [<a href="#rid69">69-71,74-77</a>].</p><p>T cell-induced autoimmune mechanisms have also been implicated in the development of the portal vein injury [<a href="#rid78">78</a>]. In one report, sinusoidal infiltration with CD 8+ cytotoxic T cells was observed in 14 of 44 patients (32 percent) [<a href="#rid72">72</a>]. The T cells were located mainly in the atrophic areas and were adjacent to endothelial cells exhibiting evidence of apoptosis. The authors speculated that transient T cell-induced endothelial injury may be the trigger for the development of INCPH. Another study found that 77 percent of patients with INCPH had antiphospholipid antibodies, possibly indicating an antibody-dependent autoimmune mechanism [<a href="#rid79">79</a>].</p><p>A study involving transcriptomic analysis in liver tissue samples from 20 patients with PSVD has shown that such patients have a unique transcriptomic profile with deregulation of pathways involved in vascular homeostasis suggesting that this may be a main pathogenic event of disease development [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The most common clinical presentation is variceal bleeding, which (in contrast to variceal bleeding in cirrhosis) is often relatively well tolerated due to the preserved liver function. In the late stages of the disease or following an episode of gastrointestinal bleeding, patients will occasionally develop jaundice, ascites, or hepatic encephalopathy. Hepatopulmonary syndrome has been described and reverses after liver transplantation [<a href="#rid81">81-83</a>]. Development of portal vein thrombosis is a frequent event during the natural course of the disease, particularly in patients with associated HIV infection or who have previously bled [<a href="#rid84">84</a>]. </p><p>On examination, splenomegaly (&gt;10 cm below the left subcostal margin) is present in more than 95 percent of patients. Dilated superficial abdominal veins can be seen in 15 percent of patients, and mild hepatomegaly (&lt;4 cm below the right subcostal margin) can be found in 50 percent of patients [<a href="#rid85">85</a>]. Other stigmata of chronic liver disease are usually absent.</p><p>Liver biochemical tests are usually normal or nearly normal [<a href="#rid38">38,71,74</a>]. Anemia, leukopenia, and thrombocytopenia are common because of hypersplenism. (See  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'</a>.) In some patients, hematologic alterations may also be caused by a hematologic-associated condition.</p><p>On imaging, the appearance of the liver may be normal or show changes similar to those found in patients with cirrhosis. (See  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Radiologic findings'</a>.)</p><p>Liver imaging may also show benign regenerative nodules that typically appear isoechoic on ultrasound. However, some nodules may be hypoechoic, often with a hypoechoic rim, and these features are also seen with hepatic metastases [<a href="#rid36">36,86</a>].<strong> </strong>On computed tomography (CT) scan,<strong> </strong>nodules may be hypodense [<a href="#rid36">36,86</a>], while on MRI, nodules appear isointense on T2-weighted images and they contain foci of high intensity on T1-weighted images [<a href="#rid36">36,87-89</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of INCPH (PSVD with portal hypertension) is made by the presence of portal hypertension (manifested by esophageal and/or gastric varices, portal hypertensive bleeding and/or portosystemic shunting on imaging), while excluding cirrhosis and other causes noncirrhotic portal hypertension with liver biopsy [<a href="#rid1">1,35,90</a>]. (See <a class="local">'Etiology'</a> above.)</p><p>Liver biopsy may show obliterative portal venopathy, nodular regenerative hyperplasia, and/or incomplete septal cirrhosis. </p><p>The diagnosis of PSVD without portal hypertension is also based on histologic findings on liver biopsy, however, these patients do not have portal hypertension. In a series of 2500 autopsies, histologic findings consistent with INCPH were found in 3 percent. However, of that 3 percent, only 5 percent had evidence of PH [<a href="#rid91">91</a>]. </p><p class="headingAnchor" id="H64321128"><span class="h3">Diagnostic approach</span><span class="headingEndMark"> — </span>The diagnostic approach in a patient suspected of having INCPH includes the following: laboratory tests to rule out other causes of liver disease/noncirrhotic portal hypertension, history of drug or toxin exposure, hepatic imaging to rule out portal or hepatic vein occlusion, liver stiffness measurement and liver biopsy to rule out cirrhosis and to identify histological features associated with PSVD/INCPH.</p><p>Patients should be evaluated for the disorders associated with INCPH  (<a class="graphic graphic_table graphicRef50663" href="/d/graphic/50663.html" rel="external">table 2</a>) if they have signs or symptoms of any of the conditions, hematologic manifestations of a myeloproliferative disease on the complete blood count and differential, prior thrombotic events that might reflect an underlying hypercoagulable state, or manifestations suggestive of a systemic disease associated with vascular injury (eg, vasculitis, lupus). (See  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a> and <a class="local">'Etiology'</a> above.)</p><p class="headingAnchor" id="H165946062"><span class="h3">Laboratory tests</span><span class="headingEndMark"> — </span>We obtain laboratory studies to evaluate for risk factors for cirrhosis and portal hypertension; the etiology of cirrhosis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Etiologies and classification'</a>.)</p><p>A report has suggested that serum vitamin B12 levels are significantly lower in patients with INCPH than in patients with cirrhosis and may be useful in distinguishing between the two entities [<a href="#rid92">92</a>]. However, the potential diagnostic role of serum vitamin B12 levels has not been validated. Similarly, it has been suggested, but not yet validated, that a group of serum metabolites detected by metabolomics may aid with diagnosing INCPH [<a href="#rid93">93</a>] or the presence of antiendothelial cells antibodies may aid with diagnosing INCPH/PSVD [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Imaging</span><span class="headingEndMark"> — </span>An imaging test is required to evaluate the liver parenchyma and circulation. The portal and hepatic veins in INCPH should be patent on imaging (eg, Doppler ultrasound, CT angiography, or MRI angiography). Patients with advanced disease may have secondary portal vein thrombosis, which may be misdiagnosed as primary extrahepatic portal vein thrombosis or thrombosis secondary to underlying cirrhosis. The clinical history, liver stiffness values, and liver biopsy findings may help to differentiate between these entities.</p><p class="headingAnchor" id="H625703682"><span class="h3">Liver stiffness</span><span class="headingEndMark"> — </span>A patient with INCPH should have a liver stiffness value on transient elastography that is usually below the expected value for a patient with cirrhosis and portal hypertension (ie, &lt;13 kPa) [<a href="#rid95">95</a>]. This can be helpful in differentiating patients with portal vein thrombosis due to cirrhosis from those with portal vein thrombosis in the setting of INCPH [<a href="#rid50">50</a>]. A multicenter study has shown that a liver stiffness value of &lt;10 kPa strongly correlated with PSVD in patients with signs of portal hypertension. Conversely, when liver stiffness is &gt;20 kPa, a diagnosis of PSVD is highly unlikely [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography", section on 'Transient elastography'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Liver pathology</span><span class="headingEndMark"> — </span>A liver biopsy is required for the diagnosis of INCPH. From a clinical perspective, the most important reason to obtain a liver biopsy in the evaluation of INCPH is to exclude the presence of cirrhosis and other specific disease entities that could account for the development of portal hypertension. Diagnosis requires a pathologist with expertise in liver disease and a sufficient tissue sample for histologic analysis, which can usually be obtained with a percutaneous or transjugular liver biopsy [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/d/html/3587.html" rel="external">"Approach to liver biopsy"</a>.)</p><p>Gross pathology of the liver surface in patients with INCPH is normal in most patients, but it is markedly nodular in 10 to 15 percent of patients, with nodularity confined to the liver's surface [<a href="#rid41">41</a>]. The portal vein and its branches are prominent with sclerosed walls. Autopsy specimens often demonstrate the presence of thrombi in the small and medium portal vein branches [<a href="#rid98">98</a>].</p><p>The histologic findings associated with INCPH can be classified into three subtypes of INCPH: </p><p class="bulletIndent1"><span class="glyph">●</span>Obliterative portal venopathy is defined by the presence of phlebosclerosis of the small and medium branches of the portal vein. This is characterized by increased portal connective tissue around the vessels with irregular wall thickening and eccentric narrowing of the vessel lumen [<a href="#rid2">2,99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular regenerative hyperplasia is defined by micronodular transformation of the liver parenchyma, with central hyperplasia, an atrophic rim, and no fibrosis [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incomplete septal cirrhosis is defined by slender, incomplete septal fibrosis that demarcates the liver parenchyma into nodules. The portal tracts are hypoplastic and hepatocytes are hyperplastic [<a href="#rid2">2</a>].</p><p></p><p>Some patients may have features of more than one subtype. Some of the variability in histologic findings among patients may be the result of heterogeneity in the disease and its severity and because of sampling variability on liver biopsy specimens  (<a class="graphic graphic_table graphicRef80624" href="/d/graphic/80624.html" rel="external">table 3</a>) [<a href="#rid37">37,41,62,100</a>].</p><p>Other histologic findings include aberrant thin-walled vessels radiating from the portal tract into the periportal space (and sometimes into the lobules where they may have pseudoangiomatous appearance [<a href="#rid13">13</a>]), dilatation of sinusoids due to increased portal pressure, and emergence of new aberrant portal channels  (<a class="graphic graphic_picture graphicRef63404 graphicRef51618" href="/d/graphic/63404.html" rel="external">picture 3A-B</a>) [<a href="#rid99">99</a>]. In advanced cases, parenchymal atrophy in the subcapsular regions may lead to collapse [<a href="#rid37">37,100-102</a>]. Uncommon histologic features include pseudonodules, piecemeal necrosis, and regenerative activity [<a href="#rid98">98</a>]. Regenerative nodules may develop near the hilum of atrophic livers in advanced cases. Electron microscopy has revealed widening of the space of Disse with fibrogenesis in the perisinusoidal space leading to capillarization of the sinusoids in some patients [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Hemodynamics</span><span class="headingEndMark"> — </span>Measurement of the hepatic venous pressure gradient (HVPG) is useful in the evaluation of patients with suspected INCPH. Although the intrasplenic and portal vein pressures are markedly elevated in patients with INCPH [<a href="#rid103">103,104</a>], the wedged hepatic vein pressure (WHVP) is normal or only slightly elevated in many patients. As a result, the HVPG is often normal or only mildly elevated despite the clinical severity of portal hypertension. This is due to the presence of hepatic vein-to-vein communications, which are frequently seen during venography, but also because of the presinusoidal component of portal hypertension in INCPH. In both situations, the WHVP almost always underestimates the true portal pressure [<a href="#rid105">105,106</a>]. Demonstration of hepatic vein-to-vein communication during hepatic venography is also supportive of the diagnosis. (See  <a class="medical medical_review" href="/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Hepatic venous pressure gradient'</a>.) Hence, the presence of unequivocal signs of portal hypertension (such as large esophageal varices and splenomegaly combined with HVPG values that are much lower than the cutoff for clinically significant portal hypertension in cirrhosis [ie, HVPG &lt;10 mmHg]) is strongly suggestive of the diagnosis of INCPH [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H64320430"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes portal hypertension due to cirrhosis of any etiology and a variety of pre-, intra-, or postsinusoidal disorders associated with portal hypertension  (<a class="graphic graphic_table graphicRef76516" href="/d/graphic/76516.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above and <a class="local">'Diagnostic approach'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h2">Management</span><span class="headingEndMark"> — </span>The focus of management for patients with INCPH is preventing and treating variceal hemorrhage. While data are limited in this population regarding the best approach [<a href="#rid84">84,108-112</a>], patients are typically managed in the same manner as those with portal hypertension due to cirrhosis. A cohort study of patients with INCPH reported good long-term outcomes using a management strategy based on guidelines for varices in the setting of cirrhosis [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a> and  <a class="medical medical_review" href="/d/html/1252.html" rel="external">"Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p>Other elements of management include withdrawing drugs associated with INCPH and treating associated medical conditions  (<a class="graphic graphic_table graphicRef50663" href="/d/graphic/50663.html" rel="external">table 2</a>). As an example, biochemical and histologic improvement or reversibility has been reported after stopping <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> in organ transplantation recipients [<a href="#rid87">87,113</a>]. In addition, patients with INCPH should be screened for portal vein thrombosis (eg, with Doppler ultrasonography every six months [<a href="#rid25">25</a>]). (See <a class="local">'Etiology'</a> above.)</p><p>Management of patients with acute variceal bleeding is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a>.)</p><p class="headingAnchor" id="H1543171122"><span class="h3">Nonselective beta blockers and endoscopic variceal ligation</span><span class="headingEndMark"> — </span>Primary and secondary prevention of variceal bleeding include the use of nonselective beta blockers and endoscopic variceal ligation. Data from cohort studies suggest that strategies based on the recommendations for management of cirrhotic portal hypertension can be applied to patients with noncirrhotic portal hypertension, and that this approach results in similar outcomes [<a href="#rid84">84,114</a>].</p><p class="headingAnchor" id="H1854138629"><span class="h3">Transjugular intrahepatic portosystemic shunt (TIPS)</span><span class="headingEndMark"> — </span>TIPS is an option for treatment of complications of INCPH, but should be avoided in patients with poor renal function, ascites, and significant extrahepatic comorbidities (eg, prothrombotic condition, hematologic malignancy, solid organ transplantation). In a study of 41 patients with INCPH who underwent TIPS with a mean follow-up of 27 months, 7 of 25 patients with a history of variceal bleeding had recurrent bleeding (28 percent). The risk of mortality was higher in patients with extrahepatic comorbidities and elevated creatinine [<a href="#rid115">115</a>]. </p><p class="headingAnchor" id="H568848246"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Several other interventions for INCPH have been reported [<a href="#rid41">41,112,116</a>]. Portosystemic shunt surgery has been shown to be an effective alternative for patients who fail endoscopic therapy [<a href="#rid117">117-119</a>]. However, shunt surgery has largely been replaced by TIPS. Splenectomy has been described in patients with symptomatic hypersplenism (spontaneous bleeding episodes, severe transfusion-dependent anemia, or repeated splenic infarcts) [<a href="#rid41">41</a>]. Case reports of patients with INCPH have also described splenic embolization and percutaneous transhepatic obliteration [<a href="#rid112">112,116</a>]. However, whether the benefit of these invasive interventions outweighs the risk is uncertain, and they are not routinely performed.</p><p class="headingAnchor" id="H4292450976"><span class="h3">Liver transplantation</span><span class="headingEndMark"> — </span>The indications for liver transplantation in patients with INCPH are similar to those for patients with cirrhosis and end-stage liver disease. Outcome data on liver transplantation in this setting are limited; small case series suggest that survival rates are favorable [<a href="#rid69">69</a>]. The risk of recurrence of INCPH after liver transplantation is not well-defined, but some cases of recurrent INCPH have been reported [<a href="#rid120">120</a>]. </p><p class="headingAnchor" id="H1525512962"><span class="h3">Anticoagulation</span><span class="headingEndMark"> — </span>The role of anticoagulation in the management of INCPH remains unclear because of a lack of high-quality data demonstrating a benefit. INCPH is often associated with an underlying prothrombotic condition, and portal vein thrombosis frequently develops in patients with INCPH. Anticoagulation is not used for preventing portal vein thrombosis, but may be an option for patients with a hypercoagulable disorder [<a href="#rid97">97</a>]. </p><p>The management of portal vein thrombosis in patients with INCPH is similar to the approach for patients with cirrhosis [<a href="#rid84">84</a>], and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.) </p><p class="headingAnchor" id="H21"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Because of preserved liver function, the prognosis of patients with INCPH is better than that of patients with cirrhosis who have a similar degree of portal hypertension. Ten-year survival rates ranging from 56 to 82 percent have been reported for patients with INCPH [<a href="#rid84">84,121</a>]. However, a subgroup of patients progresses to develop advanced hepatic insufficiency, eventually requiring liver transplantation [<a href="#rid122">122,123</a>]. These patients generally have nodular transformation of the liver with extensive hepatic and portal fibrosis. A few case reports have suggested an association between INCPH and hepatocellular carcinoma, but whether other risk factors may have accounted for the observation is unclear [<a href="#rid124">124,125</a>]. Screening for hepatocellular carcinoma is not recommended for these patients. However, hypervascular benign lesions similar to focal nodular hyperplasia have been reported in 14 percent of patients with INCPH, and may be difficult to distinguish from HCC [<a href="#rid126">126</a>]. </p><p>There are very few studies evaluating the long-term prognosis of patients with INCPH:</p><p class="bulletIndent1"><span class="glyph">●</span>One cohort study of Western patients suggested that overall survival was poorer compared with that of the general population, with a transplant-free survival of only 40 percent at 10 years [<a href="#rid121">121</a>]. However, the increased mortality in this study was related to non-liver related conditions and not to complications of portal hypertension or liver failure. Only 4 of 62 patients (6.5 percent) died from liver-related conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, another study reported good long-term outcomes in patients with biopsy-proven INCPH, with a 10-year transplant-free survival rate of 82 percent [<a href="#rid84">84</a>].</p><p></p><p>In both studies, the development of ascites was identified as a poor prognostic factor in patients with INCPH. In the latter study, the presence of a severe associated disorder (immunological disease or malignancy) was also identified as a poor prognostic factor [<a href="#rid84">84</a>].</p><p>Limited data have suggested that rates of sarcopenia in patients with INCPH were not significantly different compared with patients with compensated cirrhosis [<a href="#rid127">127</a>].</p><p>The prognosis for patients with PSVD without portal hypertension appears more favorable than INCPH (ie, PSVD with portal hypertension). In a study including 91 patients with PSVD without or with portal hypertension, PSVD alone was associated with lower rates of liver decompensation after three years compared with PSVD with clinical signs of portal hypertension (0 versus 11 percent) [<a href="#rid128">128</a>]. In addition, liver-related mortality rates were lower in patients with PSVD alone compared with PSVD with portal hypertension (0 percent versus 7 percent).</p><p class="headingAnchor" id="H2251068476"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114698.html" rel="external">"Society guideline links: Portal hypertension and ascites"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis is the most common cause of portal hypertension, but portal hypertension can also occur in the absence of cirrhosis, a condition referred to as "noncirrhotic portal hypertension." The causes of noncirrhotic portal hypertension can be divided into prehepatic, intrahepatic (presinusoidal, sinusoidal, and postsinusoidal), and posthepatic causes  (<a class="graphic graphic_table graphicRef76516" href="/d/graphic/76516.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Schistosomiasis is one of the most common causes of noncirrhotic portal hypertension worldwide [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly, and splenomegaly with hypersplenism. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of schistosomiasis can be made by the detection of schistosomal eggs in the stool. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition to treating the underlying parasitic infection, management is aimed at preventing or treating the consequences of portal hypertension (predominantly variceal bleeding). (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a> and  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic noncirrhotic portal hypertension (INCPH) is a clinical entity characterized by portal hypertension in the absence of all of the following: biopsy-proven cirrhosis, obstruction of extrahepatic portal vein or hepatic venous outflow tract, and other causes of noncirrhotic portal hypertension. The term porto-sinusoidal vascular disease (PSVD) includes patients with histologic features of INCPH but who do not have portal hypertension; in addition, PSVD does not exclude patients with portal vein thrombosis or with other chronic liver diseases. (See <a class="local">'Idiopathic noncirrhotic portal hypertension/Porto-sinusoidal vascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common clinical presentation of INCPH is variceal bleeding, which is often relatively well tolerated due to preserved liver function. Development of portal vein thrombosis is a frequent event during the course of the disease. (See <a class="local">'Clinical manifestations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic approach in a patient suspected of having INCPH includes the following: laboratory tests to rule out other causes of liver disease/noncirrhotic portal hypertension, hepatic imaging to rule out portal or hepatic vein occlusion, and liver biopsy to rule out cirrhosis. The differential diagnosis includes portal hypertension due to cirrhosis of any etiology and a variety of pre-, intra-, or postsinusoidal disorders associated with portal hypertension  (<a class="graphic graphic_table graphicRef76516" href="/d/graphic/76516.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of INCPH is aimed at preventing or treating the consequences of portal hypertension (predominantly variceal bleeding). While data are limited in this population regarding the best approach to management, patients are typically managed in the same manner as those with portal hypertension due to cirrhosis. Patients also undergo screening for portal vein thrombosis (eg, with Doppler ultrasonography every six months). (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a> and  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54:1071.</a></li><li><a class="nounderline abstract_t">De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol 2019; 4:399.</a></li><li><a class="nounderline abstract_t">Morris JS, Schmid M, Newman S, et al. Arsenic and noncirrhotic portal hypertension. Gastroenterology 1974; 66:86.</a></li><li><a class="nounderline abstract_t">Datta DV, Mitra SK, Chhuttani PN, Chakravarti RN. Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India. Gut 1979; 20:378.</a></li><li><a class="nounderline abstract_t">Sarin SK, Sharma G, Banerjee S, et al. Hepatic fibrogenesis using chronic arsenic ingestion: studies in a murine model. Indian J Exp Biol 1999; 37:147.</a></li><li><a class="nounderline abstract_t">Smith PM, Crossley IR, Williams DM. Portal hypertension in vinyl-chloride production workers. Lancet 1976; 2:602.</a></li><li><a class="nounderline abstract_t">Dunn MA, Kamel R. Hepatic schistosomiasis. Hepatology 1981; 1:653.</a></li><li><a class="nounderline abstract_t">El-Garem AA. Schistosomiasis. Digestion 1998; 59:589.</a></li><li><a class="nounderline abstract_t">Nakashima, T. Liver cirrhosis. Human cases. Acta Hepatol Jpn 1969; 10:485.</a></li><li><a class="nounderline abstract_t">Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am 1992; 21:163.</a></li><li><a class="nounderline abstract_t">Denié C, Vachiery F, Elman A, et al. Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver 1996; 16:309.</a></li><li><a class="nounderline abstract_t">Mies S, Neto OB, Beer A Jr, et al. Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol. Dig Dis Sci 1997; 42:751.</a></li><li><a class="nounderline abstract_t">Pereira LM, Melo MC, Saleh MG, et al. Hepatitis C virus infection in Schistosomiasis mansoni in Brazil. J Med Virol 1995; 45:423.</a></li><li><a class="nounderline abstract_t">Pereira LM, Melo MC, Lacerda C, et al. Hepatitis B virus infection in schistosomiasis mansoni. J Med Virol 1994; 42:203.</a></li><li><a class="nounderline abstract_t">Strickland GT, Elhefni H, Salman T, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67:436.</a></li><li><a class="nounderline abstract_t">de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study. Hepatogastroenterology 2003; 50:2028.</a></li><li><a class="nounderline abstract_t">Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol Rev 2004; 201:156.</a></li><li><a class="nounderline abstract_t">Tamarozzi F, Fittipaldo VA, Orth HM, et al. Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature. PLoS Negl Trop Dis 2021; 15:e0009191.</a></li><li><a class="nounderline abstract_t">Abdel-Wahab MF, Esmat G, Farrag A, et al. Ultrasonographic prediction of esophageal varices in Schistosomiasis mansoni. Am J Gastroenterol 1993; 88:560.</a></li><li><a class="nounderline abstract_t">Richter J, Correia Dacal AR, Vergetti Siqueira JG, et al. Sonographic prediction of variceal bleeding in patients with liver fibrosis due to Schistosoma mansoni. Trop Med Int Health 1998; 3:728.</a></li><li><a class="nounderline abstract_t">Giannini EG, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol 2006; 101:2511.</a></li><li><a class="nounderline abstract_t">Xu XD, Xu CF, Dai JJ, et al. Ratio of platelet count/spleen diameter predicted the presence of esophageal varices in patients with schistosomiasis liver cirrhosis. Eur J Gastroenterol Hepatol 2016; 28:588.</a></li><li><a class="nounderline abstract_t">Berhe N, Gundersen SG, Abebe F, et al. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 1999; 72:53.</a></li><li><a class="nounderline abstract_t">Davis A, Wegner DH. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ 1979; 57:767.</a></li><li><a class="nounderline abstract_t">de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022; 76:959.</a></li><li><a class="nounderline abstract_t">el Tourabi H, el Amin AA, Shaheen M, et al. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol 1994; 88:493.</a></li><li><a class="nounderline abstract_t">Ede CJ, Nikolova D, Brand M. Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis. Cochrane Database Syst Rev 2018; 8:CD011717.</a></li><li><a class="nounderline abstract_t">da Silva LC, Strauss E, Gayotto LC, et al. A randomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann Surg 1986; 204:148.</a></li><li><a class="nounderline abstract_t">Andersson KL, Chung RT. Hepatic schistosomiasis. Curr Treat Options Gastroenterol 2007; 10:504.</a></li><li><a class="nounderline abstract_t">Costa Lacet CM, Neto JB, Ribeiro LT, et al. Schistosomal portal hypertension: Randomized trial comparing endoscopic therapy alone or preceded by esophagogastric devascularization and splenectomy. Ann Hepatol 2016; 15:738.</a></li><li><a class="nounderline abstract_t">Raia S, da Silva LC, Gayotto LC, et al. Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 1994; 20:398.</a></li><li><a class="nounderline abstract_t">Liu J, Zhou B, Chen D, et al. Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Schistosomiasis-Induced Liver Fibrosis. Cardiovasc Intervent Radiol 2019; 42:1760.</a></li><li><a class="nounderline abstract_t">Guido M, Sarcognato S, Sonzogni A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int 2016; 36:454.</a></li><li><a class="nounderline abstract_t">Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol 2011; 54:455.</a></li><li><a class="nounderline abstract_t">Kmeid M, Liu X, Ballentine S, Lee H. Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data. Gastroenterology Res 2021; 14:49.</a></li><li><a class="nounderline abstract_t">Mahamid J, Miselevich I, Attias D, et al. Nodular regenerative hyperplasia associated with idiopathic thrombocytopenic purpura in a young girl: a case report and review of the literature. J Pediatr Gastroenterol Nutr 2005; 41:251.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195.</a></li><li><a class="nounderline abstract_t">Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12:94.</a></li><li><a class="nounderline abstract_t">Sarin SK, Kumar A, Chawla YK, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int 2007; 1:398.</a></li><li><a class="nounderline abstract_t">Vakili C, Farahvash MJ, Bynum TE. "Endemic" idiopathic portal hypertension: report on 32 patients with non-cirrhotic portal fibrosis. World J Surg 1992; 16:118.</a></li><li><a class="nounderline abstract_t">Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17:526.</a></li><li><a class="nounderline abstract_t">Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol 2002; 17 Suppl 3:S204.</a></li><li><a class="nounderline abstract_t">Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion 1998; 59:420.</a></li><li><a class="nounderline abstract_t">Kono K, Ohnishi K, Omata M, et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988; 94:787.</a></li><li><a class="nounderline abstract_t">Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536.</a></li><li><a class="nounderline abstract_t">Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23:1511.</a></li><li><a class="nounderline abstract_t">Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49:626.</a></li><li><a class="nounderline abstract_t">Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103.</a></li><li><a class="nounderline abstract_t">Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167.</a></li><li><a class="nounderline abstract_t">Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104:1707.</a></li><li><a class="nounderline abstract_t">Schouten JN, Van der Ende ME, Koëter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther 2012; 36:875.</a></li><li><a class="nounderline abstract_t">Cachay ER, Peterson MR, Goicoechea M, Mathews WC. Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study. Br J Med Med Res 2011; 1:346.</a></li><li><a class="nounderline abstract_t">Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011; 24:12.</a></li><li><a class="nounderline abstract_t">Nayyar AK, Sharma BK, Sarin SK, et al. Characterization of peripheral blood lymphocytes in patients with non-cirrhotic portal fibrosis: a comparison with cirrhotics and healthy controls. J Gastroenterol Hepatol 1990; 5:554.</a></li><li><a class="nounderline abstract_t">Tokushige K, Komatsu T, Ohzu K, et al. A defective autologous mixed lymphocyte reaction in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1992; 7:270.</a></li><li><a class="nounderline abstract_t">Saito K, Nakanuma Y, Takegoshi K, et al. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology 1993; 40:163.</a></li><li><a class="nounderline abstract_t">Inagaki H, Nonami T, Kawagoe T, et al. Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol 2000; 35:235.</a></li><li><a class="nounderline abstract_t">Tsuneyama K, Harada K, Katayanagi K, et al. Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J Gastroenterol Hepatol 2002; 17:217.</a></li><li><a class="nounderline abstract_t">Pulvirenti F, Pentassuglio I, Milito C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. J Immunol Res 2014; 2014:672458.</a></li><li><a class="nounderline abstract_t">Vilarinho S, Sari S, Yilmaz G, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology 2016; 63:1977.</a></li><li><a class="nounderline abstract_t">Sarin SK, Mehra NK, Agarwal A, et al. Familial aggregation in noncirrhotic portal fibrosis: a report of four families. Am J Gastroenterol 1987; 82:1130.</a></li><li><a class="nounderline abstract_t">Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:275.</a></li><li><a class="nounderline abstract_t">Köksal AS, Köklü S, Ibiş M, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis. Dig Dis Sci 2007; 52:3493.</a></li><li><a class="nounderline abstract_t">Yamaguchi E, Yamanoi A, Ono T, Nagasue N. Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. J Gastroenterol Hepatol 2007; 22:1134.</a></li><li><a class="nounderline abstract_t">Kamath PS, Tyce GM, Miller VM, et al. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999; 30:401.</a></li><li><a class="nounderline abstract_t">Kamath PS, Carpenter HA, Lloyd RV, et al. Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl 2000; 6:596.</a></li><li><a class="nounderline abstract_t">Sato Y, Sawada S, Kozaka K, et al. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci 2007; 52:1987.</a></li><li><a class="nounderline abstract_t">Morikawa H, Tamori A, Nishiguchi S, et al. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007; 13:240.</a></li><li><a class="nounderline abstract_t">Krasinskas AM, Eghtesad B, Kamath PS, et al. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11:627.</a></li><li><a class="nounderline abstract_t">Ibarrola C, Colina F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology 2003; 42:251.</a></li><li><a class="nounderline abstract_t">Buchel O, Roskams T, Van Damme B, et al. Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia. Gut 2005; 54:1021.</a></li><li><a class="nounderline abstract_t">Ziol M, Poirel H, Kountchou GN, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol 2004; 35:1241.</a></li><li><a class="nounderline abstract_t">Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol 2002; 35:345.</a></li><li><a class="nounderline abstract_t">Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004; 75:225.</a></li><li><a class="nounderline abstract_t">Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44:7.</a></li><li><a class="nounderline abstract_t">Podevin P, Spiridon G, Terris B, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006; 20:313.</a></li><li><a class="nounderline abstract_t">Reynolds WJ, Wanless IR. Nodular regenerative hyperplasia of the liver in a patient with rheumatoid vasculitis: a morphometric study suggesting a role for hepatic arteritis in the pathogenesis. J Rheumatol 1984; 11:838.</a></li><li><a class="nounderline abstract_t">Biecker E, Trebicka J, Fischer HP, et al. Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease. Z Gastroenterol 2006; 44:395.</a></li><li><a class="nounderline abstract_t">Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver--a manifestation of 'organ-specific antiphospholipid syndrome'? Immunobiology 2003; 207:51.</a></li><li><a class="nounderline abstract_t">Hernández-Gea V, Campreciós G, Betancourt F, et al. Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. J Hepatol 2021; 75:924.</a></li><li><a class="nounderline abstract_t">Babbs C, Warnes TW, Haboubi NY. Non-cirrhotic portal hypertension with hypoxaemia. Gut 1988; 29:129.</a></li><li><a class="nounderline abstract_t">Anand AC, Mukherjee D, Rao KS, Seth AK. Hepatopulmonary syndrome: prevalence and clinical profile. Indian J Gastroenterol 2001; 20:24.</a></li><li><a class="nounderline abstract_t">Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858.</a></li><li><a class="nounderline abstract_t">Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology 2014; 59:2276.</a></li><li><a class="nounderline abstract_t">Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002; 17:6.</a></li><li><a class="nounderline abstract_t">Grattagliano A, Rapaccini GL, Caturelli E, et al. Nodular regenerative hyperplasia of the liver: ultrasonographic appearance and echo-guided bioptic diagnosis. Ital J Gastroenterol 1994; 26:349.</a></li><li><a class="nounderline abstract_t">Seiderer J, Zech CJ, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553.</a></li><li><a class="nounderline abstract_t">Horita T, Tsutsumi A, Takeda T, et al. Significance of magnetic resonance imaging in the diagnosis of nodular regenerative hyperplasia of the liver complicated with systemic lupus erythematosus: a case report and review of the literature. Lupus 2002; 11:193.</a></li><li><a class="nounderline abstract_t">Rha SE, Lee MG, Lee YS, et al. Nodular regenerative hyperplasia of the liver in Budd-Chiari syndrome: CT and MR features. Abdom Imaging 2000; 25:255.</a></li><li class="breakAll">Okuda K, Nakashima T, Kameda H, et al. Idiopathic portal hypertension: a national study. In: Hepatology: a Festschrift for Hans Popper, Brunner H, Thaler H (Eds), Raven Press, New York 1985. p.95.</li><li><a class="nounderline abstract_t">Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11:787.</a></li><li><a class="nounderline abstract_t">Goel A, Ramakrishna B, Muliyil J, et al. Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. Dig Dis Sci 2013; 58:179.</a></li><li><a class="nounderline abstract_t">Seijo S, Lozano JJ, Alonso C, et al. Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension. Am J Gastroenterol 2013; 108:926.</a></li><li><a class="nounderline abstract_t">Cerda Reyes E, González-Navarro EA, Magaz M, et al. Autoimmune biomarkers in porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. Liver Int 2021; 41:2171.</a></li><li><a class="nounderline abstract_t">Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960.</a></li><li><a class="nounderline abstract_t">Elkrief L, Lazareth M, Chevret S, et al. Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology 2021; 74:364.</a></li><li><a class="nounderline abstract_t">Hernández-Gea V, Baiges A, Turon F, Garcia-Pagán JC. Idiopathic Portal Hypertension. Hepatology 2018; 68:2413.</a></li><li><a class="nounderline abstract_t">Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis 2002; 22:59.</a></li><li><a class="nounderline abstract_t">Nayak NC, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch Pathol 1969; 87:359.</a></li><li><a class="nounderline abstract_t">Ludwig J, Hashimoto E, Obata H, Baldus WP. Idiopathic portal hypertension; a histopathological study of 26 Japanese cases. Histopathology 1993; 22:227.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 2001; 197:65.</a></li><li><a class="nounderline abstract_t">Aikat BK, Bhusnurmath SR, Chhuttani PN, et al. The pathology of noncirrhotic portal fibrosis: a review of 32 autopsy cases. Hum Pathol 1979; 10:405.</a></li><li><a class="nounderline abstract_t">Sarin SK, Sethi KK, Nanda R. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis. Gut 1987; 28:260.</a></li><li><a class="nounderline abstract_t">Ohnishi K, Sato S, Nomura F, Iida S. Splanchnic hemodynamics in idiopathic portal hypertension: comparison with chronic persistent hepatitis. Am J Gastroenterol 1989; 84:403.</a></li><li><a class="nounderline abstract_t">Okuda K, Kono K, Ohnishi K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 1984; 86:600.</a></li><li><a class="nounderline abstract_t">Futagawa S, Fukazawa M, Musha H, et al. Hepatic venography in noncirrhotic idiopathic portal hypertension. Comparison with cirrhosis of the liver. Radiology 1981; 141:303.</a></li><li><a class="nounderline abstract_t">Seijo S, Reverter E, Miquel R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 2012; 44:855.</a></li><li><a class="nounderline abstract_t">Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997; 26:826.</a></li><li><a class="nounderline abstract_t">Kochhar R, Goenka MK, Mehta SK. Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction. Gastrointest Endosc 1991; 37:460.</a></li><li><a class="nounderline abstract_t">Kiire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. BMJ 1989; 298:1363.</a></li><li><a class="nounderline abstract_t">Sarin SK, Gupta N, Jha SK, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010; 139:1238.</a></li><li><a class="nounderline abstract_t">Hirota S, Ichikawa S, Matsumoto S, et al. Interventional radiologic treatment for idiopathic portal hypertension. Cardiovasc Intervent Radiol 1999; 22:311.</a></li><li><a class="nounderline abstract_t">Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20:88.</a></li><li><a class="nounderline abstract_t">Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 2016; 63:1640.</a></li><li><a class="nounderline abstract_t">Bissonnette J, Garcia-Pagán JC, Albillos A, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology 2016; 64:224.</a></li><li><a class="nounderline abstract_t">Doki N, Irisawa H, Takada S, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med 2007; 46:187.</a></li><li><a class="nounderline abstract_t">Mathur SK, Shah SR, Nagral SS, Soonawala ZF. Transabdominal extensive esophagogastric devascularization with gastroesophageal stapling for management of noncirrhotic portal hypertension: long-term results. World J Surg 1999; 23:1168.</a></li><li><a class="nounderline abstract_t">Pal S, Radhakrishna P, Sahni P, et al. Prophylactic surgery in non-cirrhotic portal fibrosis:is it worthwhile? Indian J Gastroenterol 2005; 24:239.</a></li><li><a class="nounderline abstract_t">Karagul S, Yagci MA, Tardu A, et al. Portosystemic Shunt Surgery in Patients with Idiopathic Noncirrhotic Portal Hypertension. Ann Transplant 2016; 21:317.</a></li><li><a class="nounderline abstract_t">Dumortier J, Bizollon T, Scoazec JY, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol 2001; 36:417.</a></li><li><a class="nounderline abstract_t">Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther 2012; 35:1424.</a></li><li><a class="nounderline abstract_t">Bernard PH, Le Bail B, Cransac M, et al. Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol 1995; 22:495.</a></li><li><a class="nounderline abstract_t">Isabel Fiel M, Thung SN, Hytiroglou P, et al. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am J Surg Pathol 2007; 31:607.</a></li><li><a class="nounderline abstract_t">Isobe Y, Yamasaki T, Yokoyama Y, et al. Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. J Gastroenterol 2007; 42:407.</a></li><li><a class="nounderline abstract_t">Hidaka H, Ohbu M, Kokubu S, et al. Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers. J Gastroenterol Hepatol 2005; 20:493.</a></li><li><a class="nounderline abstract_t">Glatard AS, Hillaire S, d'Assignies G, et al. Obliterative portal venopathy: findings at CT imaging. Radiology 2012; 263:741.</a></li><li><a class="nounderline abstract_t">Lattanzi B, Gioia S, Di Cola S, et al. Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int 2019; 39:1937.</a></li><li><a class="nounderline abstract_t">Wöran K, Semmler G, Jachs M, et al. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. Clin Gastroenterol Hepatol 2022; 20:e251.</a></li></ol></div><div id="topicVersionRevision">Topic 3580 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21574171" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Idiopathic noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30957754" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Porto-sinusoidal vascular disease: proposal and description of a novel entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4809505" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Arsenic and noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/468068" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10641134" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatic fibrogenesis using chronic arsenic ingestion: studies in a murine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/61343" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Portal hypertension in vinyl-chloride production workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7030909" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatic schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9705541" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568771" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hepatosplenic schistosomiasis. Pathophysiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938631" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9125644" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7545213" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepatitis C virus infection in Schistosomiasis mansoni in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158115" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatitis B virus infection in schistosomiasis mansoni.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12452500" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Role of hepatitis C infection in chronic liver disease in Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14696458" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361239" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Immunopathogenesis of schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33764979" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8470638" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ultrasonographic prediction of esophageal varices in Schistosomiasis mansoni.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9754668" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sonographic prediction of variceal bleeding in patients with liver fibrosis due to Schistosoma mansoni.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17029607" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26862932" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ratio of platelet count/spleen diameter predicted the presence of esophageal varices in patients with schistosomiasis liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9924961" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/317254" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multicentre trials of praziquantel in human schistosomiasis: design and techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35120736" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Baveno VII - Renewing consensus in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979639" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073663" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3090954" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221611" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hepatic schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27493113" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 :  Schistosomal portal hypertension: Randomized trial comparing endoscopic therapy alone or preceded by esophagogastric devascularization and splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8045501" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31363898" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Schistosomiasis-Induced Liver Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264219" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Obliterative portal venopathy without portal hypertension: an underestimated condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21087805" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Obliterative portal venopathy: portal hypertension is not always present at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34007347" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16056109" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nodular regenerative hyperplasia associated with idiopathic thrombocytopenic purpura in a young girl: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8729037" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007779" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19669336" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1290252" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : "Endemic" idiopathic portal hypertension: report on 32 patients with non-cirrhotic portal fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084024" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Non-cirrhotic portal fibrosis: current concepts and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472938" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Non-cirrhotic portal hypertension versus idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9693222" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276575" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17640321" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19512859" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19589079" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18389904" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18639498" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19471257" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22971050" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22268001" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21157331" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Noncirrhotic portal hypertension in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2129827" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Characterization of peripheral blood lymphocytes in patients with non-cirrhotic portal fibrosis: a comparison with cirrhotics and healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535230" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A defective autologous mixed lymphocyte reaction in patients with idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8509048" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755694" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Idiopathic portal hypertension associated with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966956" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24741616" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26874653" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3499813" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Familial aggregation in noncirrhotic portal fibrosis: a report of four families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117894" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404864" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17608860" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421647" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980059" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417733" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17622321" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915493" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Liver transplantation for severe intrahepatic noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12605645" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951553" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492992" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352299" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Connective tissue diseases and the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15054815" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799965" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Nodular regenerative hyperplasia: not all nodules are created equal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511439" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6520840" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Nodular regenerative hyperplasia of the liver in a patient with rheumatoid vasculitis: a morphometric study suggesting a role for hepatic arteritis in the pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688657" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638904" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nodular regenerative hyperplasia (NRH) of the liver--a manifestation of 'organ-specific antiphospholipid syndrome'?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34052252" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343007" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Non-cirrhotic portal hypertension with hypoxaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11206870" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hepatopulmonary syndrome: prevalence and clinical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16425397" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24155091" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Idiopathic portal hypertension: natural history and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895549" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7812029" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nodular regenerative hyperplasia of the liver: ultrasonographic appearance and echo-guided bioptic diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16607155" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11999886" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Significance of magnetic resonance imaging in the diagnosis of nodular regenerative hyperplasia of the liver complicated with systemic lupus erythematosus: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10823445" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Nodular regenerative hyperplasia of the liver in Budd-Chiari syndrome: CT and MR features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10823445" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Nodular regenerative hyperplasia of the liver in Budd-Chiari syndrome: CT and MR features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189821" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918688" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419380" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34173316" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autoimmune biomarkers in porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18395077" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33345307" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30066417" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Idiopathic Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11928079" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Idiopathic portal hypertension and its pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5766763" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8495956" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Idiopathic portal hypertension; a histopathological study of 26 Japanese cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11261820" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/468224" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The pathology of noncirrhotic portal fibrosis: a review of 32 autopsy cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3570030" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2929561" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Splanchnic hemodynamics in idiopathic portal hypertension: comparison with chronic persistent hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6698361" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7291551" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Hepatic venography in noncirrhotic idiopathic portal hypertension. Comparison with cirrhosis of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22721839" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126795" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1916169" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2502256" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547163" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10415221" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Interventional radiologic treatment for idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020909" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Nodular regenerative hyperplasia of the liver graft after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799606" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26990687" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301514" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10501880" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Transabdominal extensive esophagogastric devascularization with gastroesophageal stapling for management of noncirrhotic portal hypertension: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16424619" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Prophylactic surgery in non-cirrhotic portal fibrosis:is it worthwhile?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194018" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Portosystemic Shunt Surgery in Patients with Idiopathic Noncirrhotic Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11336168" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22536808" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7665869" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414109" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530368" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740501" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474672" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Obliterative portal venopathy: findings at CT imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31152475" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33279774" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
